Core Viewpoint - Cooper Medical (COO.US) experienced a significant decline of over 12%, reaching a year-low of $64.92, despite reporting a 6% revenue growth in Q3, aligning with analyst expectations [1] Financial Performance - The company's Q3 revenue increased to $1.06 billion, meeting analyst forecasts [1] - Adjusted earnings per share (EPS) were reported at $1.10, exceeding expectations by $0.03 [1] Future Guidance - The company revised its revenue guidance for the fiscal year 2025 to a range of $4.08 billion to $4.1 billion, down from the previous guidance of $4.11 billion to $4.15 billion [1] - On a positive note, the adjusted EPS forecast was raised to a range of $4.08 to $4.12, up from the prior range of $4.05 to $4.11 [1]